Lyra Therapeutics reported a net loss of $8.5 million for Q1 2025, a significant improvement from $22.5 million in Q1 2024. This was primarily driven by a substantial reduction in research and development expenses. The company anticipates topline results from its ENLIGHTEN 2 pivotal Phase 3 clinical trial in Q2 2025 and plans a reverse stock split to maintain Nasdaq listing.

Lyra Therapeutics reported a net loss of $11.0 million for the fourth quarter of 2024, an improvement from $15.1 million in the same period last year. The company's total operating expenses decreased to $97.882 million from $68.678 million in the prior year, primarily due to reduced clinical and employee-related costs. Cash and cash equivalents stood at $40.6 million, sufficient to fund operations into Q1 2026.

Lyra Therapeutics reported its Q3 2024 financial results, highlighting the anticipation of key milestones from the ongoing ENLIGHTEN Phase 3 trials and the topline safety data from the ENLIGHTEN 1 safety extension study. The company's cash, cash equivalents, and short-term investments were $51.6 million as of September 30, 2024, expected to fund operations into the first quarter of 2026.

Lyra Therapeutics reported its Q2 2024 financial results, highlighting ongoing Phase 3 trials for LYR-210 and cost-cutting measures, including a workforce reduction. Further analysis of the ENLIGHTEN 1 data revealed that LYR-210 demonstrated improvement over control in symptomatic endpoints in the CRS patient cohort with nasal polyps.

Lyra Therapeutics reported a net loss of $22.5 million for Q1 2024, compared to a net loss of $16.3 million for the same period in 2023. Cash, cash equivalents, and short-term investments totaled $87.1 million as of March 31, 2024. The company anticipates its cash balance will fund operations into the first quarter of 2025.

Lyra Therapeutics reported its Q4 and full year 2023 financial results, highlighting upcoming milestones for their product candidates LYR-210 and LYR-220, including topline results from the ENLIGHTEN I Phase 3 trial expected in Q2 2024. The company's cash runway is projected into the first quarter of 2025.

Lyra Therapeutics reported its Q3 2023 financial results, highlighting positive data from the BEACON Phase 2 clinical trial of LYR-220 and the completion of enrollment in the ENLIGHTEN I pivotal Phase 3 trial of LYR-210. The company's cash, cash equivalents, and short-term investments totaled $102.6 million as of September 30, 2023, expected to fund operations into the first quarter of 2025.

Lyra Therapeutics reported a net loss of $15.6 million for the second quarter of 2023. The company's cash, cash equivalents, and short-term investments totaled $116.2 million as of June 30, 2023, which is expected to fund operations into the first quarter of 2025. The company is advancing its clinical programs for LYR-210 and LYR-220.

Lyra Therapeutics reported a net loss of $16.3 million for the first quarter of 2023, compared to a net loss of $11.9 million for the same period in 2022. Cash, cash equivalents, and short-term investments were $82.7 million as of March 31, 2023.

Lyra Therapeutics reported a net loss of $14.2 million for the fourth quarter of 2022. The company's cash, cash equivalents, and short-term investments were $97.9 million as of December 31, 2022, and are expected to fund operations into mid-2024. The company transitioned manufacturing to in-house in Q4 2022.

Lyra Therapeutics reported its Q3 2022 financial results, highlighting the advancement of their ENLIGHTEN I pivotal Phase 3 trial of LYR-210 in Chronic Rhinosinusitis (CRS) and the prioritization of in-house manufacturing capabilities. Enrollment in the ENLIGHTEN II trial is temporarily paused to align with manufacturing timelines, with resumption expected in Q3 2023. The company's cash and cash equivalents were reported as $109.6 million as of September 30, 2022, expected to fund operations through mid-2024.

Lyra Therapeutics reported a net loss of $14.5 million for the quarter ended June 30, 2022. The company's cash and cash equivalents as of June 30, 2022 were $120.7 million, which is expected to fund planned operations through mid-2024. Enrollment is ongoing for the ENLIGHTEN I Phase 3 trial, and the first patient was treated in Australia in the Part 1/non-randomized portion of the BEACON Phase 2 trial.

Lyra Therapeutics reported a net loss of $7.0 million for the first quarter of 2022. The company's cash and cash equivalents were $33.8 million as of March 31, 2022, and it secured $100.5 million in gross proceeds from a private placement in April 2022.

Lyra Therapeutics reported a net loss of $13.6 million for the fourth quarter of 2021. The company's cash and cash equivalents were $45.7 million as of December 31, 2021. Key milestones included the initiation of the Phase 3 ENLIGHTEN I clinical trial for LYR-210 and the Phase 2 BEACON trial for LYR-220.

Lyra Therapeutics reported a net loss of $11.1 million for the third quarter of 2021. The company's cash and cash equivalents were $58.1 million as of September 30, 2021, and they expect this to be sufficient to fund operations through 2022.

Lyra Therapeutics reported a net loss of $11.0 million for the second quarter of 2021. The company's cash and cash equivalents were $69.0 million as of June 30, 2021, and they expect it to fund operations into 2023. They also announced a licensing agreement with LianBio for LYR-210 and have a clear path forward to advance LYR-210 into Phase 3 clinical development.

Lyra Therapeutics reported a net loss of $7.8 million for the first quarter of 2021, with cash and cash equivalents totaling $66.1 million as of March 31, 2021. The company presented positive data from its LANTERN Phase 2 study of LYR-210 and appointed Robert Kern, MD, as Chief Medical Officer.

Lyra Therapeutics announced positive topline data from their LANTERN Phase 2 Study for LYR-210 and strengthened their team with the additions of Dr. Kern to the management team and Dr. Snyderman to the board. Cash and cash equivalents were $74.6 million as of December 31, 2020.

Lyra Therapeutics reported its Q3 2020 financial results, highlighting that the company is on track to report topline Phase 2 results for LYR-210 in December 2020. The company's cash position is expected to fund operations through a planned Phase 3 study of LYR-210.

Lyra Therapeutics reported a net loss of $4.5 million for the second quarter of 2020. The company's cash and cash equivalents increased to $86.6 million due to proceeds from its IPO.

Lyra Therapeutics reported a net loss of $4.2 million for the first quarter of 2020. The company's cash and cash equivalents were $35.2 million as of March 31, 2020, which does not include the proceeds from the company's IPO.